Parathyroid hormone oral - Unigene
Alternative Names: 768974; GSK 768974; PTH 1-31; PTH 131A; PTH oral - UnigeneLatest Information Update: 24 Oct 2021
At a glance
- Originator Unigene Laboratories
- Class Calcium regulators; Osteoporosis therapies; Peptide hormones; Recombinant proteins
- Mechanism of Action Osteogenesis stimulants; Parathyroid hormone receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes - Postmenopausal osteoporosis
Highest Development Phases
- Discontinued Postmenopausal osteoporosis
Most Recent Events
- 02 Jul 2013 Discontinued - Phase-II for Postmenopausal osteoporosis in USA (PO)
- 08 Mar 2012 Parathyroid hormone oral - Unigene is available for licensing (\www.unigene.com\)
- 06 Dec 2011 Unigene terminates exclusive worldwide license agreement with GlaxoSmithKline and regains all rights to its oral parathyroid hormone product